New targeted drug HRS-6093 enters human trials for Hard-to-Treat KRAS G12D cancers

NCT ID NCT07134998

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 18 times

Summary

This early-phase study tests a new drug called HRS-6093 in 153 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants must have tried standard treatments without success or be unable to take them.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

Contact
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED KRAS G12D MUTANT SOLID TUMORS